
Anne F. Schott, MD
Advertisement
Articles by Anne F. Schott, MD



24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

This second edition of the text edited by Bland and Copeland represents a comprehensive reference that reviews the history, pathobiology, and current clinical management of diseases of the breast. Much more than a book about breast
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Nivolumab-Based Treatment Yields Long-Term Survival in Resectable NSCLC
2
Frontline IO-Combos, Next-Generation ADCs: Evolutions in Endometrial Cancer
3
Reprogramming T Cells: The Promise of In Vivo Site-Specific CAR Engineering
4
Endometrial Cancer Treatment Options: What are the Experts Using?
5
